French National Health Insurance Reports Findings in COVID-19 [Does Measles, Mumps, and Rubella (MMR) Vaccination Protect against COVID-19 Outcomes: A Nationwide Cohort Study]: Coronavirus – COVID-19

2022 DEC 07 (NewsRx) -- By a News Reporter-Staff News Editor at NewsRx COVID-19 Daily -- New research on Coronavirus - COVID-19 is the subject of a report. According to news reporting from Saint-Denis, France, by NewsRx journalists, research stated, “Cross-protection from previous live attenuated vaccines is proposed to explain the low impact of COVID-19 on children. This study aimed to evaluate the effect of live attenuated MMR vaccines on the risk of being hospitalized for COVID-19 in children.”

The news correspondents obtained a quote from the research from French National Health Insurance, “An exposed (MMR vaccine)-non-exposed cohort study was conducted using the nationwide French National Health Data System (SNDS). We included children born between 1 January 2009 and 31 December 2019. Exposure was defined as a claim of at least one dose of MMR vaccine since birth. Hospitalization for COVID-19 was defined using main diagnostic ICD10 codes. Non-conditional logistic regression was used to calculate the adjusted odds ratios (aORs) of the association between MMR exposure and hospitalization for COVID-19, controlling for socio-demographic and socio-economic factors, co-morbidities, and general health. In total, 6,800,542 (median age 6 IQR [3-8] years) children exposed to a MMR vaccine and 384,162 (6 [3-9] years) not exposed were followed up with for 18 months. Among them, 873 exposed to the MMR vaccine and 38 who were not exposed were hospitalized for COVID-19. In a multi-variate analysis, the exposure of children to MMR vaccination was not associated with a decreased risk of COVID-19 hospitalization versus non-exposure (aOR (95%CI) = 1.09 [0.81-1.48]). A stratified analysis by age showed an aOR = 1.03 [0.64-1.66] for children aged 1-4, an aOR = 1.38 [0.82-2.31] for those aged 5-9, and an aOR = 1.11 [0.54-2.29] for those aged 10-12.”

According to the news reporters, the research concluded: “Our study suggests that the live attenuated MMR vaccine does not protect children against COVID-19 hospitalization.”

For more information on this research see: Does Measles, Mumps, and Rubella (MMR) Vaccination Protect against COVID-19 Outcomes: A Nationwide Cohort Study. Vaccines, 2022;10(11):1938. Vaccines can be contacted at: Mdpi, St Alban-Anlage 66, Ch-4052 Basel, Switzerland.

Our news journalists report that additional information may be obtained by contacting Alain Weill, EPI-PHARE (Scientific Interest Group in Epidemiology of Health Products), French National Agency for the Safety of Medicines and Health Products, French National Health Insurance, CEDEX, 93285 Saint-Denis, France. Additional authors for this research include Epiphane Kolla, David Desplas, Laura Semenzato, Mahmoud Zureik and Lamiae Grimaldi.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.3390/vaccines10111938. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Publisher contact information for the journal Vaccines is: Mdpi, St Alban-Anlage 66, Ch-4052 Basel, Switzerland.

(Our reports deliver fact-based news of research and discoveries from around the world.)